Compare YI & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YI | NOTV |
|---|---|---|
| Founded | 2010 | 1974 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1M | 29.9M |
| IPO Year | N/A | 1997 |
| Metric | YI | NOTV |
|---|---|---|
| Price | $3.76 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 11.8K | ★ 1.6M |
| Earning Date | 12-05-2025 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,979,883,442.00 | $513,024,000.00 |
| Revenue This Year | N/A | $6.26 |
| Revenue Next Year | N/A | $45.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $3.19 | $0.66 |
| 52 Week High | $11.35 | $6.48 |
| Indicator | YI | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 38.48 |
| Support Level | $3.32 | $0.79 |
| Resistance Level | $3.94 | $0.86 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 67.07 | 29.12 |
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.